Ayrshire Capital Management LLC Has $6 Million Stake in Insulet Co. (NASDAQ:PODD)

Ayrshire Capital Management LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 34.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 22,988 shares of the medical instruments supplier’s stock after purchasing an additional 5,911 shares during the quarter. Insulet accounts for about 2.9% of Ayrshire Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Ayrshire Capital Management LLC’s holdings in Insulet were worth $6,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of PODD. Baillie Gifford & Co. boosted its stake in shares of Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after buying an additional 389,639 shares during the last quarter. Geode Capital Management LLC boosted its position in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Clearbridge Investments LLC grew its stake in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PODD shares. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Wells Fargo & Company boosted their price target on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Finally, Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus target price of $272.81.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is currently owned by insiders.

Insulet Trading Down 1.4 %

Shares of PODD stock opened at $267.99 on Tuesday. The stock has a 50 day simple moving average of $264.57 and a 200 day simple moving average of $230.93. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.80 billion, a P/E ratio of 45.89, a price-to-earnings-growth ratio of 4.12 and a beta of 1.22.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.